Need help in rewriting this in my own words please

(Exicure, Inc 2022).

Currently Exicure, Inc has a market share of $16.99 million and their CAGR from the

past three to five years is 14.48% which is the same as GeoVax, it just tells us that Exicure is a

good company to attract investors.

Finally, we have Benitech Biopharma Inc, which is a development-stage biotechnology

company that is engaged in the discovery, development, and commercialization of therapeutic

agents capable of addressing medical needs and replacing the traditional approach to treat

genetic disorders. I could not find any mission statement or values on their website, but they are

committed to silencing disease-causing genes. Take a look at the table below to view their

current pipeline:

(Benitech Biopharma Inc 2022).

They are currently in the process of testing their vaccine for BB-301 which will treat

Oculopharyngeal Muscular Dystrophy, this is the lead program in their pipeline, their second

program is testing for BB-103 which is a treatment for chronic hepatitis B and they are currently

seeking partners to advance BB-103.

Benitech's market share is currently valued at $2.45 billion and their CAGR for the last

three to five years is 11.2% which makes them less favorable to investors but they also have a lot

less in their pipelines compared to the other competitors, but since they are seeking a partner to

develop their BB-103 product further this might be a hindrance to them.